论文部分内容阅读
目的探讨c-erbB-2、雌激素受体(estrogen receptor,ER)和孕激素受体(progesterone receptor,PR)在乳腺癌组织中的表达及其与预后的临床意义。方法采用免疫组织化学S-P法检测193例乳腺癌组织中c-erbB-2、ER及PR的表达。结果 c-erbB-2、ER及PR的阳性表达率分别为40.9%、62.0%和58.0%;其中c-erbB-2的阳性表达与组织病理学分型、临床分期、腋淋巴结转移有相关性,c-erbB-2阳性表达组的5年总生存率明显低于阴性表达组;ER与PR的表达呈显著正相关关系(P﹤0.01),c-erbB-2与ER、PR之间的表达呈负相关(P﹤0.05)。结论检测乳腺癌组织中c-erbB-2和ER、PR的表达对乳腺癌患者治疗方案的制定和判断预后有重要意义。
Objective To investigate the expression of c-erbB-2, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer and its clinical significance. Methods The expressions of c-erbB-2, ER and PR in 193 cases of breast cancer were detected by immunohistochemical S-P method. Results The positive expression rates of c-erbB-2, ER and PR were 40.9%, 62.0% and 58.0% respectively. The positive expression of c-erbB-2 was correlated with histopathological type, clinical stage and axillary lymph node metastasis, The 5-year overall survival rate of c-erbB-2 positive group was significantly lower than that of negative group (P <0.01). The expression of c-erbB-2 was positively correlated with PR, Was negatively correlated (P <0.05). Conclusion Detection of c-erbB-2, ER and PR in breast cancer tissue is important for the development of therapeutic regimen and prognosis in patients with breast cancer.